Trials / Recruiting
RecruitingNCT05764954
A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma
A Prospective Clinical Trial of Tumor Immunomodulation Using Tumor-Treating Fields (TTFields) in Patients With Early-Stage Resectable Lung Adenocarcinoma
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 22 Years
- Healthy volunteers
- Not accepted
Summary
The researchers are doing this study to find out if treatment with TTFields using the NovoTTF-200T System is safe and practical (feasible) before surgical removal (resection) of lung adenocarcinoma (ADC). The researchers will also look at how the treatment may help the body's immune system to fight cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | NovoTTF-200T System | The device is applied continuously for an average duration of 18 hours per day for 3 weeks (+/- 1 week). |
Timeline
- Start date
- 2023-08-04
- Primary completion
- 2027-08-01
- Completion
- 2027-08-01
- First posted
- 2023-03-13
- Last updated
- 2026-04-09
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT05764954. Inclusion in this directory is not an endorsement.